TrialJournal for immunotherapy of cancer2018

A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer.

Walburga Engel-Riedel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.